Back to Search
Start Over
Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer: Excellent Response to 177 Lu-PSMA With No Adrenal Insufficiency.
- Source :
-
Clinical nuclear medicine [Clin Nucl Med] 2024 Jan 01; Vol. 49 (1), pp. e8-e9. Date of Electronic Publication: 2023 Nov 22. - Publication Year :
- 2024
-
Abstract
- Abstract: We present isolated bilateral adrenal metastases successfully treated with 177 Lu-PSMA in a 66-year-old man diagnosed with castration-resistant prostate cancer. The patient had progression under chemotherapy as depicted by 68 Ga-PSMA PET/CT showing intense bilateral PSMA uptake in the adrenal masses, and metastasis-directed therapies were considered as the first option for improving survival because the patient was oligometastatic. However, surgery and radiotherapy were not justifiable options due to the high risk of definitive adrenal insufficiency; therefore, the patient received 4 cycles of 177 Lu-PSMA treatment. 68 Ga-PSMA PET/CT showed near-complete response in bilateral adrenal metastases, and no sign of adrenal insufficiency was observed during follow-up.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Male
Humans
Aged
Positron Emission Tomography Computed Tomography
Treatment Outcome
Radiopharmaceuticals therapeutic use
Prostate-Specific Antigen
Dipeptides therapeutic use
Heterocyclic Compounds, 1-Ring therapeutic use
Retrospective Studies
Prostatic Neoplasms, Castration-Resistant pathology
Adrenal Insufficiency drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1536-0229
- Volume :
- 49
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Clinical nuclear medicine
- Publication Type :
- Academic Journal
- Accession number :
- 37991439
- Full Text :
- https://doi.org/10.1097/RLU.0000000000004964